26
Participants
Start Date
October 6, 2021
Primary Completion Date
November 17, 2021
Study Completion Date
October 24, 2022
Ad26.ZEBOV
"Ad26.ZEBOV is a non-replicating, monovalent vaccine expressing the full-length Mayinga glycoprotein (GP) of the Ebola virus (formerly known as Zaire ebolavirus), and is produced in human cell line.~Participants will receive a 0.5mL intramuscular injection of Ad26.ZEBOV, at a concentration of 1x10\^11 vp/mL, into the anterolateral deltoid muscle."
KAVI - Institute of Clinical Research, Nairobi
MRC/UVRI and LSHTM Uganda Research Unit, Masaka
London School of Hygiene and Tropical Medicine
OTHER